# Daehwa Pharmaceutical

Source: https://onco.cc/companies/daehwa-pharmaceutical/  
OnCo record `daehwa-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Daehwa is a Korean pharmaceutical company whose oral paclitaxel (Liporaxel) was approved in Korea for gastric cancer after a phase 3 trial it led, one of the few oral formulations of a taxane to reach the market.

## Summary

Daehwa Pharmaceutical Co., Ltd., founded in 1984 and based in Seoul, developed Liporaxel, an oral liquid formulation of paclitaxel that uses a lipid-based system to achieve absorption, and won Korean approval for advanced gastric cancer on a phase 3 trial against intravenous paclitaxel. Further phase 3 trials in breast cancer are registered on ClinicalTrials.gov under Daehwa as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Daehwa Pharmaceutical Co., Ltd.; Dae Hwa Pharm; 대화제약
- Tags: ctgov-sponsor
- HQ: Seoul
- Type: pharma
- Website: http://www.dhpharm.co.kr

## Sources

- Official website: http://www.dhpharm.co.kr
- ClinicalTrials.gov: trials led by Daehwa Pharmaceutical Co., Ltd.: https://clinicaltrials.gov/search?lead=Daehwa%20Pharmaceutical%20Co.%2C%20Ltd.
- Wikidata: https://www.wikidata.org/wiki/Q56583329

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/daehwa-pharmaceutical.json